5033414D02Rik Activators
5033414D02Rik activators comprise a diverse array of compounds that enhance the protein's functionality by influencing various signaling pathways. Forskolin, through the elevation of cAMP, indirectly augments 5033414D02Rik by activating PKA, which is known to phosphorylate a multitude of substrates, potentially including those associated with 5033414D02Rik function. Genistein contributes to this enhancement by inhibiting tyrosine kinases, thereby reducing competitive signaling and possibly leading to an indirect increase in 5033414D02Rik activity. The lipid signaling molecule sphingosine-1-phosphate and the calcium homeostasis disruptor thapsigargin both play roles in the modulation of signaling pathways that intersect with 5033414D02Rik activity, with sphingosine-1-phosphate acting through its specific receptors and thapsigargin elevating intracellular calcium levels, which may activate calcium-dependent proteins that interact with 5033414D02Rik.
Additionally, the activators include compounds that target kinase signaling pathways, such as PMA, which stimulates5033414D02Rik activators comprise a diverse array of compounds that enhance the protein's functionality by influencing various signaling pathways. Forskolin, through the elevation of cAMP, indirectly augments 5033414D02Rik by activating PKA, which is known to phosphorylate a multitude of substrates, potentially including those associated with 5033414D02Rik function. Genistein contributes to this enhancement by inhibiting tyrosine kinases, thereby reducing competitive signaling and possibly leading to an indirect increase in 5033414D02Rik activity. The lipid signaling molecule sphingosine-1-phosphate and the calcium homeostasis disruptor thapsigargin both play roles in the modulation of signaling pathways that intersect with 5033414D02Rik activity, with sphingosine-1-phosphate acting through its specific receptors and thapsigargin elevating intracellular calcium levels, which may activate calcium-dependent proteins that interact with 5033414D02Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can lead to activation of 5033414D02Rik by decreasing competitive tyrosine kinase signaling, which may indirectly enhance 5033414D02Rik activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors, leading to downstream signaling events that can indirectly increase the activity of 5033414D02Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis, which can indirectly boost 5033414D02Rik activity through calcium-dependent signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may enhance the signaling pathways involving 5033414D02Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several kinases, potentially altering signaling cascades that lead to the enhanced activity of 5033414D02Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate PI3K/Akt signaling, indirectly promoting 5033414D02Rik activity by influencing related downstream signaling processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, could enhance 5033414D02Rik function by altering the PI3K/Akt pathway, which is potentially linked to the regulation of 5033414D02Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, could indirectly enhance 5033414D02Rik activity by shifting the signaling equilibrium towards pathways that involve 5033414D02Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, potentially enhancing 5033414D02Rik activity through calcium-dependent signaling mechanisms. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine broadly inhibits protein kinases, which could release certain inhibitory controls on pathways involving 5033414D02Rik, thereby indirectly increasing its activity. | ||||||